SK pharmteco to participate in CPhI Worldwide in Spain

SK pharmteco, SK Inc.'s contract bio-manufacturing subsidiary, will showcase its capabilities in small molecule APIs and cell and gene therapy at the CPhI Worldwide convention in Barcelona.

A computer-generated image of SK pharmteco's booth at this year's Convention on Pharmaceutical Ingredients (CPhI) Worldwide, the world’s largest pharma trade show, set to be held in Barcelona from Oct. 24 to 26. [SK PHARMTECO]

SK pharmteco, SK Inc.’s contract bio-manufacturing subsidiary, will set up a dedicated booth at this year’s Convention on Pharmaceutical Ingredients (CPhI) Worldwide, the world’s largest pharma trade show.

The 2023 edition of the event will kick off on Oct. 24 and run for three days in Barcelona, Spain. More than 2,000 pharmaceutical suppliers and more than 40,000 industry stakeholders are likely to visit the upcoming convention.

SK pharmteco, a contract development and manufacturing organization (CDMO), plans to showcase its multi-modality contract manufacturing capabilities at this year’s event, with a focus on small molecule active pharmaceutical ingredients (APIs) and cell and gene therapy.

SK pharmteco executives including CEO Joerg Ahlgrimm, as well as representatives from its subsidiaries, such as SK biotek Ireland, Yposkesi and Center for Breakthrough Medicines (CBM), are set to attend the event.

In January last year, SK pharmteco invested $350 million in CBM to become the second largest shareholder of the Philadelphia-based CDMO specializing in cell and gene therapy (C&GT), and recently secured a controlling stake in the company.

SK pharmteco acquired Yposkesi in 2021, a French cell and gene therapy CDMO company, that completed the construction of its second plant in June. Together with the first production site, which is also located in the Genopole campus, Yposkesi became one of Europe's largest biomanufacturing facility for C&GT that spans 10,000 square meters.

SK pharmteco also said Wednesday that it has recently appointed Andrew Fenny, former chief business officer at Fujifilm Diosynth Biotechnologies (FDB), a CDMO, as its chief commercial officer.

BY SHIN HA-NEE [shin.hanee@joongang.co.kr]